TABLE 1.
In Vitro Dosimetry
| Parameter | IMR-05 | NLF |
| Mean D50 ± SEM (Gy) | ||
| 125I-KX1 | 0.18 ± 0.01 | 2.0 ± 0.1 |
| 131I-KX1 | 0.35 ± 0.01 | 3.5 ± 0.3 |
| 125I-MIBG | 1.1 ± 0.1 | 3.7 ± 0.3 |
| 211At-MM4 | 0.051 ± 0.002 | 0.56 ± 0.07 |
| 211At-NaAtx | 0.20 ± 0.01 | 1.0 ± 0.1 |
| External γ | 0.71 ± 0.02 | 3.7 ± 0.1 |
| RBE for nontargeted therapy | ||
| 125I-MIBG vs. γ | 0.65 | 1.0 |
| 211At-NaAtx vs. γ | 3.6 | 3.7 |
| 211At-NaAtx vs. 125I-MIBG | 5.5 | 3.7 |
| RBE for targeted therapy | ||
| 125I-KX1 vs. 131I-KX1 | 1.9 | 1.8 |
| 211At-MM4 vs. 131I-KX1 | 6.7 | 6.3 |
| 211At-MM4 vs. 125I-KX1 | 3.5 | 3.6 |